Eli Lilly’s existing 2024 research collaboration with Peptron gives the company non-exclusive, internal-use rights to evaluate SmartDepot’s sustained-release microsphere technology on peptide drugs, but includes no commercial licensing commitment. Recent reporting highlights Lilly’s pivot toward oral obesity candidates, which reduces near-term need for injectable long-acting formulations. No public announcements, regulatory filings, or credible leaks have signaled a formal commercial agreement, technology transfer, or binding deal in the eight months since the evaluation phase began. With the October 7, 2026 resolution date less than two months away and typical pharma licensing timelines stretching longer, traders see limited catalysts capable of flipping the outcome.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% chance
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing 2024 research collaboration with Peptron gives the company non-exclusive, internal-use rights to evaluate SmartDepot’s sustained-release microsphere technology on peptide drugs, but includes no commercial licensing commitment. Recent reporting highlights Lilly’s pivot toward oral obesity candidates, which reduces near-term need for injectable long-acting formulations. No public announcements, regulatory filings, or credible leaks have signaled a formal commercial agreement, technology transfer, or binding deal in the eight months since the evaluation phase began. With the October 7, 2026 resolution date less than two months away and typical pharma licensing timelines stretching longer, traders see limited catalysts capable of flipping the outcome.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,264End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing 2024 research collaboration with Peptron gives the company non-exclusive, internal-use rights to evaluate SmartDepot’s sustained-release microsphere technology on peptide drugs, but includes no commercial licensing commitment. Recent reporting highlights Lilly’s pivot toward oral obesity candidates, which reduces near-term need for injectable long-acting formulations. No public announcements, regulatory filings, or credible leaks have signaled a formal commercial agreement, technology transfer, or binding deal in the eight months since the evaluation phase began. With the October 7, 2026 resolution date less than two months away and typical pharma licensing timelines stretching longer, traders see limited catalysts capable of flipping the outcome.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing 2024 research collaboration with Peptron gives the company non-exclusive, internal-use rights to evaluate SmartDepot’s sustained-release microsphere technology on peptide drugs, but includes no commercial licensing commitment. Recent reporting highlights Lilly’s pivot toward oral obesity candidates, which reduces near-term need for injectable long-acting formulations. No public announcements, regulatory filings, or credible leaks have signaled a formal commercial agreement, technology transfer, or binding deal in the eight months since the evaluation phase began. With the October 7, 2026 resolution date less than two months away and typical pharma licensing timelines stretching longer, traders see limited catalysts capable of flipping the outcome.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions